liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för kardiovaskulär medicin. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Hjärt- och Medicincentrum, Kardiologiska kliniken US.ORCID-id: 0000-0001-6353-8041
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: JACC. Heart failure, ISSN 2213-1779, E-ISSN 2213-1787, Vol. 7, nr 1, s. 65-76Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

OBJECTIVES This study investigated 1-year incidence and predictors of dyskalemia (dysK) and its outcome associations in heart failure with preserved ejection fraction (HFpEF), HF with mid-range EF (HFmrEF), and HF with reduced EF (HFrEF). BACKGROUND DysK in real-world HF is insufficiently characterized. Fear of dyskalemia may lead to underuse or underdosing of renin-angiotensin-aldosterone system inhibitors. METHODS Patients enrolled in the SwedeHF (Swedish Heart Failure) Registry from 2006 to 2011 in Stockholm, Sweden were included in the analyses. Multivariate Cox regression analysis identified independent predictors of dysK within 1 year. Time-dependent Cox models assessed outcomes associated with incident dysK (all-cause death, HF, and other cardiovascular disease [CVD] hospitalizations) within 1 year from baseline. RESULTS Of 5,848 patients, 24.4% experienced hyperkalemia (hyperK [K amp;gt; 5.0 mmol/l]) at least once, and 10.2% had moderate or severe hyperK (K amp;gt; 5.5 mmol/l). Adjusted risk of moderate or severe hyperK was highest in HFpEF and HFmrEF. Similarly, 20.3% of patients had at least one episode of hypokalemia (hypoK [amp;lt;3.5 mmol/l]), and 3.7% had severe hypoK (amp;lt;3.0 mmol/l). Adjusted risk of any hypoK was highest in HFpEF. Independent predictors of both hyperK and hypoK were sex, baseline potassium and estimated glomerular filtration rate, low hemoglobin, chronic obstructive pulmonary disease (COPD), inpatient status, and higher New York Heart Association functional class. Incident dysK was associated with increased risk of mortality. Furthermore, hypoK was associated with increased CVD hospitalizations (HF-related excluded). There was no association between dysK and HF hospitalization risk, regardless of EF. CONCLUSIONS DysK is common in HF and is associated with increased mortality. Risk of moderate or severe hyperK was highest in HFpEF and HFmrEF, whereas risk of hypoK was highest in HFpEF. HF severity, low hemoglobin, COPD, baseline high and low potassium, and low eGFR were relevant predictors of dysK occurrence. (C) 2019 by the American College of Cardiology Foundation.

Ort, förlag, år, upplaga, sidor
ELSEVIER SCI LTD , 2019. Vol. 7, nr 1, s. 65-76
Nyckelord [en]
dyskalemia; heart failure; hyperkalemia; hypokalemia; mid-range ejection fraction; preserved ejection fraction; reduced ejection fraction; SCREAM; SwedeHF
Nationell ämneskategori
Kardiologi och kardiovaskulära sjukdomar
Identifikatorer
URN: urn:nbn:se:liu:diva-153970DOI: 10.1016/j.jchf.2018.10.003ISI: 000454642900010PubMedID: 30553905OAI: oai:DiVA.org:liu-153970DiVA, id: diva2:1281541
Anmärkning

Funding Agencies|Vifor Fresenius Medical Care Renal Pharma and Relypsa; Swedish Heart and Lung Foundation [20120321, 20150557]; Swedish Research Council [2013-23897-104604-23, 523-2014-2336]; Stockholm County Council (ALF projects); AstraZeneca; Martin Rinds Foundation; Westmans Foundation; Relypsa; Vifor Pharma; Novartis; Sanofi; French National Research Agency public grant, second Investissements dAvenir program FIGHT-HF [ANR-15-RHU-0004]; French PIA project Lorraine Universite dExcellence grant [ANR-15-IDEX-04-LUE]; Merck and Co.; Boehringer Ingelheim

Tillgänglig från: 2019-01-22 Skapad: 2019-01-22 Senast uppdaterad: 2025-02-10

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Dahlström, Ulf
Av organisationen
Avdelningen för kardiovaskulär medicinMedicinska fakultetenKardiologiska kliniken US
I samma tidskrift
JACC. Heart failure
Kardiologi och kardiovaskulära sjukdomar

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 47 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf